Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Artemisone - Artemis Therapeutics

Drug Profile

Artemisone - Artemis Therapeutics

Alternative Names: BAY 44-9585

Latest Information Update: 26 Jun 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Bayer; Medicines for Malaria Venture
  • Developer Artemis Therapeutics
  • Class Antimalarials; Antivirals; Epoxy compounds; Pyrans; Small molecules; Thiamorpholines
  • Mechanism of Action Free radical stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Malaria
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Malaria
  • Preclinical Cytomegalovirus infections

Most Recent Events

  • 26 Jun 2018 Artemis Therapeutics announces intention to submit IND for Cytomegalovirus infections (Artemis pipeline, June 2018)
  • 26 Jun 2018 Artemis Therapeutics completes a phase II trial in Malaria treatment in Germany prior to June 2018 (Artemis pipeline, June 2018)
  • 19 Jun 2018 Pharmacodynamics data from a preclinical trial in Malaria treatment released by Artemis Therapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top